Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
about
Understanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication.Potential Clinical and Economic Impact of Switching Branded Medications to Generics.Analyzing generic and branded substitution patterns in the Netherlands using prescription dataThe Controversy over Generic Antiepileptic Drugs.Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.Rational use of generic psychotropic drugs.Licensing of Generic Medicines: Are There Any Challenges Left? A Pharmaceutical Regulatory Perspective.Clinical experience with generic levetiracetam in people with epilepsy.Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteersSubstitution of anticonvulsant drugs.The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.Generic substitution of antiepileptic drugs.Switching from brand-name to generic psychotropic medications: a literature review.Requirements for generic antiepileptic medicines: a clinical perspective.Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies.Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review.Demand-side policies to encourage the use of generic medicines: an overview.Generic Substitution of AEDs: Is it Time to Put This Issue to Rest?Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review.Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study.Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.A Patient's Voice.Switching to generic antiepileptic drugs: growing concerns.Does substitution of brand name medications by generics differ between pharmacotherapeutic classes? A population-based cohort study in France.Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study.Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
P2860
Q33418937-C0D6D6D6-D6FD-4744-8194-30ED259B09D1Q33637817-97923FD7-54EF-4FF8-A29D-E7C9EC7C7057Q33882893-96C78A01-CF41-48DE-9F0A-C6C7947386AFQ34476865-5C164C78-6B04-44A4-8598-2A215325A5FAQ34667134-5ACB1543-3046-40FD-AC4F-D12E116C7798Q34688387-4A2914EC-B9CB-4C16-A3BC-0D1816D10A21Q35763872-3452730C-7455-4B5E-9703-70F632B9E2A8Q35845438-AB113345-C3C1-4C25-A4F5-832696ACF456Q36916999-2A61B7B5-F5D0-4619-8E9E-EA6994CBD5CCQ37053912-E7EB616D-5D4D-45BA-9E60-1E12E14D9938Q37240298-FE0FA763-A3A4-4A6B-B42A-6BC024275CFFQ37575533-AAD4DB7B-B9A4-4A48-8795-FD309976B184Q37810997-93628BE0-CB6A-485C-8C1B-AB2FEDE8A31AQ37813190-0959488D-86A7-4213-BD59-F1FBB38821F8Q37888545-0A0F3556-0F0D-49CC-AA72-345E64BEE47AQ37949570-7909242A-AD16-4C63-8A18-4952CDF01753Q37998417-02B7C842-B6E7-4C69-87BD-97A16E0233C5Q38080914-CD7FE43C-88D3-4AFE-BB85-813345B31773Q38350218-503C2592-EDDD-4F6A-A542-7E2240605DCBQ38374905-F56AEB0E-2441-449A-8B29-A0D9EDC1081FQ38532357-F9C0F504-7CA0-4930-940C-5DE080BF5405Q40512938-B5FDDB4E-FA6E-4C7D-B10E-CF9B1DAB76A2Q40706829-6F6887B8-5906-4583-8A62-E5FC9A3E9BA1Q42113189-39AC84BA-1E2B-4F3B-A3FD-92EA8D85F0CCQ42743012-9CFB204B-DBDC-48C7-9EAC-273F19A98F4AQ48107325-2508719C-7520-43E9-9AB2-695D0B346471Q50001792-73F14B4C-292E-4DCC-841A-0187ABB48A58Q52664925-F0E5D062-1EEB-4A92-8670-F94DFC166BA3Q52681366-207A1945-A7D2-4B14-9986-5569B25D1932Q55005295-343102BF-69ED-4C06-B72A-E34744D24465
P2860
Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
@en
type
label
Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
@en
prefLabel
Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
@en
P2093
P1433
P1476
Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
@en
P2093
J LeLorier
P E Paradis
P Lefebvre
R Manjunath
P304
P356
10.1212/01.WNL.0000313154.55518.25
P407
P433
P577
2008-05-01T00:00:00Z